BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Catalyst Pharma Announces Proposed Public Offering of Common Stock

  All of the shares in the offering are being sold by Catalyst.

  November 28, 2017

   · 

  3 min read
• Drug Development

  AIT Therapeutics Announces Positive Preliminary Data for the Primary Endpoint of Safety in Its NO-NTM Abscessus Phase II Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients

  The safety data, along with positive results in other key parameters, drive AIT’s decision to move the program forward and plan for a potential pivotal trial to begin in the United States in the second half of 2018.

  November 28, 2017

   · 

  8 min read
• Policy

  Aeterna Zentaris’ Marketing Authorization Application for Macrilen (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by EMA

  AGHD affects approximately 75,000 adults across the US, Canada and Europe.

  November 28, 2017

   · 

  5 min read
• 

  Business

  CIRCULOGENE Names Dr. Glen J. Weiss as CMO

  Dr. Weiss will oversee and advance the laboratory’s research efforts and further educate oncologists about CIRCULOGENE’s next-generation sequencing (NGS) technology.

  November 28, 2017

   · 

  3 min read
• Business

  Ascensia Diabetes Care and Health2Sync Announce Collaboration to Bring Digital Diabetes Management Solution to Patients In Asia

  As part of this collaboration, the companies will create a combined offering for people with diabetes that comprises of the CONTOUR PLUS or CONTOUR TS blood glucose monitoring systems from Ascensia, the Health2Sync app and a loyalty program for users, known as the Ascensia Customer Care Program.

  November 28, 2017

   · 

  3 min read
• Business

  PhaseBio Enters Worldwide License Agreement With MedImmune for a Reversal Agent for Ticagrelor

  Ticagrelor is unique among P2Y12 antagonist antiplatelet agents due to its ability to reversibly bind to the receptor, whereas other P2Y12 antagonists bind permanently.

  November 28, 2017

   · 

  3 min read
• Biotech Bay

  Cesca Therapeutics Announces Issuance of Second Cellular Processing Patent

  This advanced cell separation technology, known as Buoyancy-Activated Cell Separation, or BACS, is key to the ongoing development of Cesca’s CAR-TXpress™ platform.

  November 28, 2017

   · 

  4 min read
• Business

  G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer

  Phase 1b/2 study evaluating AstraZeneca’s Tagrisso® and G1T38 in EGFR mutation-positive non-small cell lung cancer is expected to initiate in the first quarter of 2018.

  November 28, 2017

   · 

  5 min read
• BioCapital

  CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued in December 2016 - Nov. 28, 2017

  Following the Company’s reverse split in June 2017, twenty-five (25) Series DD and Series EE warrants will be required to purchase one share at an exercise price of $4.50.

  November 28, 2017

   · 

  1 min read
• Deals

  OSI Adds Varian Truebeam to Training Center

  OSI today announced the acquisition of a Varian Truebeam Radiotherapy System.

  November 28, 2017

   · 

  2 min read